|Articles|November 1, 2019
- BioPharm International-11-01-2019
- Volume 32
- Issue 11
KUBio Box for Viral Vectors
GE Healthcare Life Sciences launched the new KUBio box for the production of viral vector-based gene therapies.
Advertisement
GE Healthcare Life Sciences launched the new KUBio box for the production of viral vector-based gene therapies. The device is the most recent addition the company’s KUBio modular bioprocessing portfolio.
Designed to fit into new facilities and retrofitted existing spaces, the new device supports up to 200-L scale manufacturing, comes equipped with a biosafety level 2 (BSL-2) modular bioprocessing environment, and features a FlexFactory single-use biomanufacturing platform specifically for the production of viral vectors.
The design also supports future expansion at different production scales and product technologies.
Articles in this issue
almost 6 years ago
Biopharma modeling, now and five years from nowalmost 6 years ago
A Diverse Landscape of Patent Issues Seen in the US, UK, and the EUalmost 6 years ago
Modeling Comes of Age in Biopharmaalmost 6 years ago
Applying Lessons Learned from the Semiconductor Industryalmost 6 years ago
What’s New in Manufacturing: Downstream Technologiesalmost 6 years ago
Zippered Lab Coatalmost 6 years ago
More Consistent Drug Inspection System on Horizonalmost 6 years ago
Signatures–What’s in a Name?almost 6 years ago
Modernizing Flu Vaccine ManufacturingNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
